BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Formation Bio Doses First Participant in Phase I Trial of Lynk’s CNS-Penetrant TYK2 Inhibitor

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...

June 11, 2026 | News

Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

June 11, 2026 | News

China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...

June 10, 2026 | News

Mabwell's First In Class Autoimmune Antibody 9MW5211 Wins China Clinical Trial Approval for IBD

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently...

June 08, 2026 | News

Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...

June 04, 2026 | News

Lynk Pharmaceuticals Advances LNK01004 Into Phase II Trials For Vitiligo And Chronic Hand Eczema

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

June 02, 2026 | News

ImmVira Reports 100% Complete Response Rate With MVR T3011 In BCG Unresponsive Bladder Cancer

ImmVira Group announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 Ameri...

June 02, 2026 | News

Leica Biosystems Expands AstraZeneca And Daiichi Sankyo Collaboration To Advance AI Driven Lung Cancer Biomarker Research

Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions,announced an expansion of its strategic coll...

June 01, 2026 | News

Antengene Receives CDE Endorsement For Pivotal Phase III Study Of CLDN18.2 ADC In Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

May 29, 2026 | News

Ribo Submits Phase 2 CTA To EMA For siRNA Therapy Targeting Coronary Artery Disease

Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application...

May 29, 2026 | News

CGBIO Expands Global NOVOSIS Partnership With DePuy Synthes Into North America And Australia

DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development...

May 28, 2026 | News

Kazia Therapeutics Expands Paxalisib TNBC Trial Following Encouraging Early Safety Data

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data Kazia Therapeutics Limited (NASDAQ...

May 28, 2026 | News

AGC Biologics Selected By Teikoku Seiyaku Co., Ltd. To Advance Microbial Manufacturing For KTP 001 Disc Herniation Therapy

AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract d...

May 27, 2026 | News

Caliway Advances Global Phase 3 Programme For CBL 514 Following U.S. FDA IND Clearance

Asia-Pacific Phase 2 Study CBL-0206 Also Approved by Australia HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy ...

May 26, 2026 | News

Stay Connected